You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
港股異動 | 鉅子生物漲超5%破頂 券商指其有望引領重組膠原蛋白髮展
格隆匯 01-13 10:09
格隆匯1月13日丨“膠原蛋白第一股”鉅子生物(2367.HK)再度拉昇漲超5%,盤中高見37.45港元創上市新高價,總市值達370億港元。申萬宏源最新研報指,鉅子生物以技術優勢為基石,打造全面品牌和產品矩陣,覆蓋功效性護膚品、醫用敷料及功能性食品等下游美麗健康行業。公司重組膠原蛋白基底深厚,未來有望持續引領中國重組膠原蛋白行業發展。該行預計22-24年公司實現歸母淨利潤9.4/12.5/16.3億元,給予公司34倍目標市盈率。23年公司合理市值在490.7億港元,首次覆蓋,給予“買入”評級。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of this article is for reference only. It does not constitute an offer, solicitation, recommendation, opinion or guarantee of any securities, financial products or instruments.The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance.
uSMART
Wealth Growth Made Easy
Open Account